Kyowa Kirin

Kyowa Kirin, based in Tokyo, listed as 4151.T and part of the Kirin group, is a Japanese biopharmaceutical company whose oncology products include mogamulizumab, sold as Poteligeo, for cutaneous T-cell lymphoma and toremifene, sold as Fareston, for metastatic breast cancer. It developed the anti-CCR4 antibody mogamulizumab, markets Fareston in the United States, and also sells burosumab as Crysvita and G-CSF products in Japan. OnCo links it to the toremifene drug record. Whether a CCR4 antibody can find uses beyond rare T-cell lymphomas is the open question for its oncology franchise. Toremifene has its own page.